Monday , September 24 2018
Home / Letter From The Editor (page 8)

Letter From The Editor

Feb. 10, 2018

As I was driving home the other night I heard a duet by Bette Midler and Barbra Streisand. The lyrics included “Anything you can do, I can do better; I can do anything better than you.” For some reason this got me thinking about the use of AI (artificial intelligence). …

Read More »

Feb. 6, 2018

Last week, after a 75-mile group cycling ride, about a dozen of us were enjoying coffee and conversation at our favorite shoppe. Since we might be considered a somewhat competitive bunch, there was a lot of chatter about who had the highest power, who won the final sprint, and any …

Read More »

Feb. 3, 2018

This would be a good week to set aside extra time to read the newsletter. There is so much information that I almost thought about splitting it up into 2 weeks but our publisher, Steve Freed, wouldn’t let me. We begin by finishing up with Part 4 of our special …

Read More »

Jan. 30, 2018

I was with about 10 other riders at breakfast recently. I happened to hear the word “diabetes” and of course my ears perked up. When I asked Russ and Randy what they were talking about, the subject was food choices and insulin resistance. Seems that one of them had heard …

Read More »

Jan. 27, 2018

The CDC and NIH are saying that this year is one of the worst ever for the flu. Patients often try OTC’s to treat the symptoms, but a lot of times respiratory problems drive them to their prescriber, and often a short course of tapering corticosteroid therapy is prescribed. This …

Read More »

Jan. 23, 2018

Over the past couple of weeks in our main newsletter, Steve has introduced you to the idea of using software that includes considerations for insurance coverage and cost to pinpoint diabetes care. However, we all know that patients with diabetes have multiple disease states and we need to maximize therapy …

Read More »

Jan 20, 2018

We have continued to add new and more effective medications for diabetes focusing on different defects in metabolism. These additions have actually put the drugs in the weird position of competing with each other and working together at the same time. This week, our newsletter is full of examples of …

Read More »

Editor’s Note

I remember when I got the call to be on an advisory board for the first SGLT-2 inhibitor. The science made sense but it seemed that everyone was worried about the “tremendous” risk of UTI’s due to excess urination and glucose in the urine. I think this came from a …

Read More »

Jan. 16, 2018

So often in patients with diabetes, there are multiple co-morbidities that can lead to premature death or at the least a decreased quality of life. There is often the question as to which disease comes first and whether the combination of these diseases worsen each other. This week, our Clinical …

Read More »

Jan. 9, 2018

Almost 100 years ago, researchers figured out that the failure of the beta cells of the pancreas led to diabetes. It was more than 25 years later when we first made the distinction between type 1 and type 2 diabetes. In the next 15 years we discovered a medicine that …

Read More »